ClinicalTrials.gg
RecruitingNCT06864130ALEXISUpdated Nov 19, 2026

A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures

A Phase 4 interventional study of Alendronate 70mg weekly in Osteoporosis in Post-menopausal Women, sponsored by Odense University Hospital. Recruiting at 8 sites in Denmark. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Odense University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 19, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.

Planned enrollment
Largest of 51
1,400 · median 60
Started
2025
the only one that year
Phase 4
17 of 51
2 open now
Registered
51st of 51
by date

Among the 51 studies testing alendronate in Osteoporosis, this one has the largest planned enrollment, is the only one that started in 2025, is one of 17 in phase 4, and was the 51st registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alendronate

Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing alendronate in Osteoporosis, or all of them as a file.
02

Study summary

The goal of this clinical trial is to study the effects of discontinuation of Alendronate treatment for three years. The participants are postmenopausal women with osteoporosis, who have had a treatment period without fractures. The study will answer:

  • What is the rate of fragility fractures during the study? The hypothesis is that discontinuation of Alendronate after a fracture-free period does not raise the 3-year fracture risk.
  • Are there predictors of significant bone loss after discontinuation of Alendronate? The hypothesis is that clinical, biochemical, cellular, or molecular characteristics can predict bone loss.

Researchers will compare the outcomes of discontinuation of Alendronate with continuing treatment. Participants will be randomly assigned to a group.

Participants will:

  • Either take alendronate once weekly for three years OR discontinue their treatment
  • Visit the clinic at 6 and 18 months for blood samples
  • Visit the clinic at the start of the study and after 1, 2, and 3 years for bone scans and blood samples.
03

Conditions studied

  • Osteoporosis in Post-menopausal Women

Browse trials for

Keywords

  • Alendronate
  • Discontinuation
  • Osteoporosis
  • Bone mineral density
  • post-menopausal
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Current treatment with Alendronate
  • Alendronate treatment >3 år AND no fracture OR
  • Alendronate treatment >5 år AND latest low energy fracture > 3 years ago

Exclusion criteria

Exclusion Criteria:

  • T-score \< - 3,5 in hip (total hip or femoral neck) or lumbar spine
  • Treatment with systemic , ongoing or within 12 months
  • Uncontrolled inflammatory disease
  • Active
  • \< 40 mL/min
  • Atypical femur fracture (ever)
  • OsteoNecrosis of the Jaw (active)
  • Unable to give inform consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,400 participants (estimated)

Study arms

  • Experimental
    Discontinuation of Alendronate

    Discontinuation of Alendronate treatment

    Drug: Alendronate 70mg weekly

  • No intervention
    Control group

    The control group will continue Alendronate treatment, but shift to project-sponsored product (70 mg Alendronate weekly)

Interventions

06

What researchers measure

Primary outcomes

  1. Fragility fractures

    Incidence of fragility fractures during the study period

    Time frame: From enrollment to the end of the 3 year study period.

Secondary outcomes

  1. Changes in bone mineral density (BMD)

    Changes in lumbar spine and total hip BMD measured by dual energy X-ray arbsorptiometry. The three follow-up scans will be analyzed by a technician blinded to participant allocation, ie this person will not meet the patient and the patient will not be able see the results of the scans until the final study visit.

    Time frame: Baseline, 12, 24 and 36 months

  2. Bone turn over marker (CTX)

    Fasting blood samples will be performed during the study period to analyze changes in carboxy-terminal collagen crosslinks (CTX).

    Time frame: Blood samples are performed at baseline, 6, 12, 18, 24, and 36 months.

  3. Bone turn over marker (P1NP)

    Fasting blood samples will be performed during the study period to analyze changes in procollagen type I N-terminal propeptide (PINP).

    Time frame: Blood samples are performed at baseline, 6, 12, 18, 24, and 36 months.

  4. Restart Criteria

    The proportion of participants meeting restart criteria during the study period. Restart criteria is defined as: Participants experiencing boneloss exceeding 10% from baseline in any region, one clinical vertebral fracture, two low energy fractures (including morphometric vertebral fracture but excluding fractures of scull, fingers or toes) are withdrawn from the study and offered treatment with alendronate or zoledronic acid after new diagnostic work-up.

    Time frame: From enrollment to the end of the study period at 3 years

  5. Adverse Events

    At baseline a thoroughly physical examination of the participants and questioning concerning any conditions or diseases will take place. This way the investigators will be able to evaluate possible changes throughout the study. Patients will be interviewed about the occurrence of AEs at each visit from the first trial related activity after the subject has signed the informed consent. Subjects that experience adverse events or develop a disease during the trial period will be managed until the condition is cured or stationary. If this is not the case at the end of the study, subjects will be referred to a relevant physician, e.g. the general practitioner or a specialist, to be followed up.

    Time frame: From enrollment to the end of the 3 year study period.

Other outcomes

  1. Osteoclastassay

    Osteoclasts differentiation, formation, activity and response to Alendronate in cultures derived from peripheal blood at baseline from a subgroup of 35 from each arm (70 participants in total).

    Time frame: Baseline

  2. Molecular bone histology

    Iliac crest bone biopsy specimens will be obtained to evaluate the effect of discontinuation of alendronate on cortical and trabecular bone resorption and formation by histomorphometry. These results will be compared with results of bone turnover markers. Biopsies will be obtained of maximum 35 from each treatment group at 12 and 36 months (in totalt 140 participants).

    Time frame: 12 and 36 months

  3. Epigenetic analysis

    Epigenetic analysis of peripheal blood with focus on the degree of methylation.

    Time frame: Baseline

  4. Body composition

    A subgroup of maximum 500 participants will be asked to participate in DXA whole body to assess lean mass and will be reported in grams. Scans will be performed using the same scanner throughout the study, and scans will be analysed by personnel blinded to group allocation.

    Time frame: Baseline, 12, 24, and 36 months.

  5. Physical activity, accelometry

    A subgroup of maximum 500 will be asked to wear an accelerometer. Wireless accelerometers will be used to assess intensity, duration, and patterns of physical activity, and sedentary behavior. Data will be continuously collected in a raw format at 50 Hz over a period of seven days.

    Time frame: Baseline and 12 months

  6. Quality of life - Short Form Survey (SF-36)

    SF-36 is a well-validated self-reported questionnaire that measures health-related quality of life. The questionnaire will be applied in Danish using version 1.1 and each item is scored on a scale from 0 to 100, where a high score indicates a more favorable health state.

    Time frame: Baseline, at 12, 24 and 36 months.

  7. Physical activity, IPAQ

    A subgroup of maximum 500 will be asked to complete a validated Danish short form of the International Physical Activity Questionnaire (IPAQ). IPAQ is reported as a score of MET-min per week. More MET-min indicates more physical activity.

    Time frame: Baseline, at 12, 24 and 36 months.

  8. Lower extremity muscle strength

    Maximal muscle strength of lower extremity strength will be assessed in 130 participants with an isokinetic dynamometer (System 4, Biodex Medical System Inc, New York, USA). Strength will be reported as Nm.

    Time frame: Baseline, at 12, 24, and 36 months

  9. Physical function

    Short physical performance battery (SPPB) will be applied to a subgroup of 130 participants and reported on a scale from 0-12.

    Time frame: Baseline, at 12, 24, and 36 months

  10. Grip strength

    Hand grip strength of 130 participants will be measured using a handheld dynamometer (Jamar Plus, Patterson Medical, Warrenville, IL, US). Strength will be reported as kg.

    Time frame: Baseline, at 12, 24, and 36 months

07

Study locations

5 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Individual anonymized data will be accessible upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Mar 2029, 48 months after the start.

Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 48 months is close to that.

Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Mar 7, 2025
StartActual
Feb 21, 2025
Primary completionEst.
Mar 1, 2029
CompletionEst.
Sep 15, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Esbjerg Og Grindsted Sygehus · Esbjerg, DenmarkNot yet recruiting→Recruiting
  • Copenhagen University Hospital (Herlev) · Herlev, DenmarkNot yet recruiting→Recruiting
  • Nordsjaellands Hospital (Hillerød) · Hillerød, DenmarkNot yet recruiting→Recruiting
Show site
  • Sygehus Sønderjylland, Tønder · Tønder, Denmark
Nov 19, 2026
Secondary outcomes
1 time frame changed, 7 added, 1 description edited
What changed in the outcomes
  • Addedother outcomeBody compositionTime frame: Baseline, 12, 24, and 36 months.
  • Addedother outcomePhysical activity, accelometryTime frame: Baseline and 12 months
  • Addedother outcomeQuality of life - Short Form Survey (SF-36)Time frame: Baseline, at 12, 24 and 36 months.
  • Addedother outcomePhysical activity, IPAQTime frame: Baseline, at 12, 24 and 36 months.
  • Addedother outcomeLower extremity muscle strengthTime frame: Baseline, at 12, 24, and 36 months
  • Addedother outcomePhysical functionTime frame: Baseline, at 12, 24, and 36 months
  • Addedother outcomeGrip strengthTime frame: Baseline, at 12, 24, and 36 months
  • Time frameother outcomeOsteoclastassayBaseline and 12 months → Baseline
  • Descriptionother outcomeOsteoclastassay: how it is measured was reworded
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    1 site added. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Esbjerg Og Grindsted Sygehus · Esbjerg, DenmarkNot yet recruiting→Recruiting
    • Copenhagen University Hospital (Herlev) · Herlev, DenmarkNot yet recruiting→Recruiting
    • Nordsjaellands Hospital (Hillerød) · Hillerød, DenmarkNot yet recruiting→Recruiting
    Show site
    • Sygehus Sønderjylland, Tønder · Tønder, Denmark
    Secondary outcomes 1 time frame changed, 7 added, 1 description edited
    What changed in the outcomes
    • Addedother outcomeBody compositionTime frame: Baseline, 12, 24, and 36 months.
    • Addedother outcomePhysical activity, accelometryTime frame: Baseline and 12 months
    • Addedother outcomeQuality of life - Short Form Survey (SF-36)Time frame: Baseline, at 12, 24 and 36 months.
    • Addedother outcomePhysical activity, IPAQTime frame: Baseline, at 12, 24 and 36 months.
    • Addedother outcomeLower extremity muscle strengthTime frame: Baseline, at 12, 24, and 36 months
    • Addedother outcomePhysical functionTime frame: Baseline, at 12, 24, and 36 months
    • Addedother outcomeGrip strengthTime frame: Baseline, at 12, 24, and 36 months
    • Time frameother outcomeOsteoclastassayBaseline and 12 months → Baseline
    • Descriptionother outcomeOsteoclastassay: how it is measured was reworded
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06864130
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Feb 21, 2025
Primary completion
Mar 1, 2029 (estimated)
Completion
Sep 15, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Pernille Hermann, MD, PhD.
Contact
pernille.herman@rsyd.dk
+4523602366
Lars Folkestad, MD, PhD.
Contact
lars.folkestad@rsyd.dk
+4529648537
Pernille Hermann, MD, PhD.
principal investigator · Odense Universitetshospital / Odense University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alendronate

Start the discussion